Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MDCXNASDAQ:NLSPNASDAQ:OKURNASDAQ:RVPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMDCXMedicus Pharma$2.79+4.5%$4.36$1.80▼$8.94$37.87MN/A136,847 shs184,090 shsNLSPNLS Pharmaceutics$2.39-1.6%$1.75$1.30▼$18.39$8.60M0.05888,202 shs107,337 shsOKUROnKure Therapeutics$2.85+0.7%$2.56$1.70▼$20.00$38.50M0.42110,825 shs39,686 shsRVPHReviva Pharmaceuticals$0.78-1.3%$0.83$0.49▼$4.28$36.46M0.111.15 million shs522,745 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMDCXMedicus Pharma-9.49%-2.91%-45.06%-22.38%+266,999,900.00%NLSPNLS Pharmaceutics-4.71%+27.89%+48.17%+58.82%+1,753.55%OKUROnKure Therapeutics-5.35%-2.08%+45.13%-38.74%+282,999,900.00%RVPHReviva Pharmaceuticals-5.61%-2.65%+1.65%-23.76%-46.79%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMDCXMedicus Pharma2.0048 of 5 stars3.80.00.00.02.90.80.0NLSPNLS PharmaceuticsN/AN/AN/AN/AN/AN/AN/AN/AOKUROnKure Therapeutics3.5264 of 5 stars3.70.00.00.03.82.51.3RVPHReviva Pharmaceuticals2.6916 of 5 stars3.61.00.00.02.53.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMDCXMedicus Pharma 3.50Strong Buy$23.50742.29% UpsideNLSPNLS Pharmaceutics 0.00N/AN/AN/AOKUROnKure Therapeutics 3.33Buy$32.331,034.50% UpsideRVPHReviva Pharmaceuticals 3.29Buy$9.001,053.85% UpsideCurrent Analyst Ratings BreakdownLatest NLSP, RVPH, MDCX, and OKUR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.006/3/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.005/29/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.005/22/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.005/20/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $3.005/12/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$14.00 ➝ $27.005/8/2025MDCXMedicus PharmaMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $20.004/30/2025OKUROnKure TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/28/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/24/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.004/21/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMDCXMedicus PharmaN/AN/AN/AN/AN/AN/ANLSPNLS PharmaceuticsN/AN/AN/AN/AN/AN/AOKUROnKure TherapeuticsN/AN/AN/AN/A$26.60 per shareN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/A$0.20 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMDCXMedicus PharmaN/AN/A0.00N/AN/AN/AN/AN/A6/27/2025 (Estimated)NLSPNLS Pharmaceutics-$12.17MN/A0.00∞N/AN/AN/AN/AN/AOKUROnKure Therapeutics-$77.39M-$5.26N/AN/AN/AN/A-51.17%-47.11%8/12/2025 (Estimated)RVPHReviva Pharmaceuticals-$39.26M-$0.79N/AN/AN/AN/AN/A-252.53%8/13/2025 (Estimated)Latest NLSP, RVPH, MDCX, and OKUR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025RVPHReviva Pharmaceuticals-$0.21-$0.13+$0.08-$0.13N/AN/A5/12/2025Q1 2025MDCXMedicus Pharma-$0.23-$0.42-$0.19-$0.42N/AN/A5/6/2025Q1 2025OKUROnKure Therapeutics-$1.41-$1.19+$0.22-$1.19N/AN/A3/31/2025Q4 2024RVPHReviva Pharmaceuticals-$0.22-$0.15+$0.07-$0.15N/AN/A3/28/2025Q4 2024MDCXMedicus Pharma-$0.32-$0.18+$0.14-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMDCXMedicus PharmaN/AN/AN/AN/AN/ANLSPNLS PharmaceuticsN/AN/AN/AN/AN/AOKUROnKure TherapeuticsN/AN/AN/AN/AN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMDCXMedicus PharmaN/AN/AN/ANLSPNLS PharmaceuticsN/A0.15N/AOKUROnKure TherapeuticsN/A23.7123.71RVPHReviva PharmaceuticalsN/A0.390.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMDCXMedicus PharmaN/ANLSPNLS PharmaceuticsN/AOKUROnKure Therapeutics90.98%RVPHReviva Pharmaceuticals63.18%Insider OwnershipCompanyInsider OwnershipMDCXMedicus PharmaN/ANLSPNLS Pharmaceutics16.40%OKUROnKure Therapeutics2.30%RVPHReviva Pharmaceuticals27.18%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMDCXMedicus PharmaN/A13.57 millionN/AN/ANLSPNLS Pharmaceutics63.60 million3.01 millionNot OptionableOKUROnKure TherapeuticsN/A13.51 million2.75 millionN/ARVPHReviva Pharmaceuticals546.74 million24.35 millionOptionableNLSP, RVPH, MDCX, and OKUR HeadlinesRecent News About These CompaniesRVPH: Open Label Extension Results & Key Opinion Leader DiscussionJune 5, 2025 | finance.yahoo.comReviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid ConferenceJune 5, 2025 | globenewswire.comReviva Pharmaceuticals' (RVPH) Buy Rating Reaffirmed at D. Boral CapitalJune 5, 2025 | americanbankingnews.comReviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in SchizophreniaJune 2, 2025 | globenewswire.comReviva to Participate in Upcoming Investor Conferences in May 2025May 20, 2025 | santelog.comReviva Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 15, 2025 | globenewswire.comReviva to Participate in the A.G.P. Healthcare Company ShowcaseMay 13, 2025 | finance.yahoo.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Icon (ICLR), Reviva Pharmaceuticals Holdings (RVPH) and SurModics (SRDX)May 4, 2025 | theglobeandmail.comReviva to Participate in the Citizens Life Sciences ConferenceApril 29, 2025 | finance.yahoo.comRVPH: M&A Deals Highlight Brilaroxazine ValueApril 7, 2025 | finance.yahoo.comRoth MKM Reaffirms Their Buy Rating on Reviva Pharmaceuticals Holdings (RVPH)April 5, 2025 | markets.businessinsider.comReviva Reports Full Year 2024 Financial Results and Recent Business HighlightsMarch 31, 2025 | markets.businessinsider.comReviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS CongressMarch 30, 2025 | globenewswire.comWhy Reviva Pharmaceuticals Holdings, Inc.’s (RVPH) Stock Is Down 10.61%March 7, 2025 | aaii.comUnusually active option classes on open February 12thFebruary 12, 2025 | markets.businessinsider.comReviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | globenewswire.comReviva to Participate in the 2025 BIO CEO & Investor ConferenceJanuary 30, 2025 | globenewswire.comReviva Pharmaceuticals price target lowered to $11 from $14 at H.C. WainwrightJanuary 22, 2025 | markets.businessinsider.comReviva Pharmaceuticals Holdings Inc (RVPH) Stock Sees Market Value Hit $93.16 million: What Are the Implications?January 22, 2025 | bovnews.comROTH MKM Issues Buy Rating for Reviva Pharmaceuticals Holdings Inc (RVPH) StockJanuary 18, 2025 | bovnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNLSP, RVPH, MDCX, and OKUR Company DescriptionsMedicus Pharma NASDAQ:MDCX$2.79 +0.12 (+4.49%) As of 04:00 PM EasternMedicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.NLS Pharmaceutics NASDAQ:NLSP$2.39 -0.04 (-1.65%) As of 04:00 PM EasternNLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.OnKure Therapeutics NASDAQ:OKUR$2.85 +0.02 (+0.71%) As of 04:00 PM EasternOnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.Reviva Pharmaceuticals NASDAQ:RVPH$0.78 -0.01 (-1.27%) As of 04:00 PM EasternReviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
